Skip to main content

Table 1 Baseline characteristics of studied patients at diagnosis

From: Clinical impact of early minimal residual disease detection at day 15 in precursor B-childhood acute lymphoblastic leukemia: an Egyptian experience

ParameterNumber n = (72)%
Sex
 Male4258.3%
  Female3041.7%
Clinical data
 Hepatomegaly4055.6%
 Splenomegaly3650%
 Lymphadenopathy5677.8%
 CNS infiltration811.1%
Laboratory dataRangeMean (± SD)
TLC (× 109/L)2.9–15047.59(34.91)
Hb (gm/dl)3.4–11.77.69(1.78)
Platelets(× 109/L)12–13272.42(30.35)
Peripheral blood blasts (%)6–8032.17(23.83)
Blasts in B.M (%)36–9871.39(18.57)
Immunophenotyping (n) (%)
- CD19 (72/72) (100%)
- HLA-Dr (72/72) (100%)
- CD10 (68/72) (94.4%)
- CD34 (66/72) (91.6%)
- CD20 (10/72) (13.8%)
- Aberrant expression (20/72) (27.7%)
• Myeloid markers (8/72) (11.1%)
• T cell marker (12/72) (16.6%)
Cytogenetics (n= 16/72) (22.2%)
- t (9;22)(BCR/ABL) (4/72) (5.6%)
- t (1;19)(TCF3/PBX1) (8/72) (11.1%)
- 11q23 rearrangement (4/72) (5.6%)
  1. TLC total leukocytic count, Hb hemoglobin, IPT immunophenotyping, PB peripheral blood, BM bone marrow